佛慈制藥(002644.SZ)舒肝消積丸和濟生橘核丸等藥品進入國家醫保目錄
格隆匯8月22日丨佛慈制藥(002644.SZ)公佈,近日,國家醫療保障局、人力資源社會保障部發布了《關於印發的通知》,公佈了《國家基本醫療保險、工傷保險和生育保險藥品目錄(2019年版)》(以下簡稱“國家醫保目錄”)。公司獨家品種舒肝消積丸兩個劑型(大蜜丸、水蜜丸)以及特色產品濟生橘核丸(濃縮丸)進入國家醫保目錄乙類範圍。截至目前,公司共有215個品規產品進入國家醫保目錄,甲類範圍128個,乙類範圍87個。
舒肝消積丸為處方藥,主要適應症及功能主治為清熱利濕,舒肝健脾,理氣化瘀;用於慢性乙型肝炎肝鬱脾虛、濕熱內藴、氣滯血瘀證,症見脅痛、脘腹脹悶,厭油膩,噁心嘔吐,疲乏無力。
濟生橘核丸為處方藥,主要適應症及功能主治為行氣軟堅,散寒止痛;用於疝氣偏墜,睾丸脹痛。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.